Compendium of TB best practices in the Russian Federation
Background
Working Group 4 (WG4) on Country Readiness, Advocacy and Community Partnership was established under the TB Vaccine Accelerator Council to help countries prepare for the introduction of new TB vaccines. With one or more vaccines for adults and adolescents expected to be approved in the coming years, WG4 focuses on supporting evidence-based decision-making, strengthening delivery systems, and building trust through partnerships with affected communities and civil society involved in both TB and immunization, to ensure timely and equitable rollout.
WG4 works through a series of country preparedness and thematic workshops that bring together national decision-makers, technical experts, and community representatives to address priority topics such as delivery systems, regulatory alignment, and demand creation. This model builds on lessons learned from successful consultations in Indonesia and South Africa since 2024, which demonstrated the value of collaborative planning and cross-sector engagement. By leveraging this experience, WG4 aims to create a structured yet flexible approach tailored to country contexts.
The Community of Practice will be the cornerstone of WG4, providing an inclusive space for countries, civil society, technical agencies and other partners to exchange experiences and co-develop strategies that address common challenges. Rather than prescribing global best practices, it will support country-led approaches while offering access to global guidance and evidence as resources. Over time, this network will strengthen capacity, build trust, and accelerate readiness for equitable TB vaccine introduction.
Objectives
Working Group 4 aims to engender country and community ownership in preparedness and adoption of novel TB vaccines, and by:
- facilitating discussions about optimal use cases and potential implementation strategies, including identification of priority populations for initial introduction where appropriate;
- proposing solutions towards health system strengthening and program co-ordination and integration;
- providing evidence for policy and procurement decision-making based on context-relevant cost-effectiveness, budget impact, and vaccine impact modelling, and identifying gaps as needed;
- establishing working relationships between country-level decision makers and key constituencies including civil society and affected communities;
- sharing learnings, exchanging models and protocols, and, where appropriate, co-developing solutions and tools for TB vaccine implementation.
Publications
WHO seeks to advance the development and deployment of new TB vaccines to prevent TB disease, with a focus on adolescents and adults in whom 90% of...
Related content
More
